![](/images/graphics-bg.png)
Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects
Joint Authors
Paragh, György
Somodi, Sándor
Seres, Ildikó
Lőrincz, Hajnalka
Fülöp, Péter
Harangi, Mariann
Source
International Journal of Endocrinology
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-05-30
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
The elevated level of plasminogen activator inhibitor-1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established.
The association of plasma PAI-1 and lipid metabolism is still unclear.
The aim of the present study was to determine the relationship between plasma PAI-1 levels and the distribution of lipoprotein subfractions in obese and lean nondiabetic individuals.
Subjects and Methods.
We enrolled fifty nondiabetic obese patients and thirty-two healthy volunteers.
Lipoprotein subfractions were detected with Lipoprint System.
Plasma PAI-1, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and myeloperoxidase (MPO) concentrations were determined with enzyme-linked immunosorbent assay (ELISA), while serum paraoxonase-1 (PON1) activities were measured by spectrophotometry.
Results.
The TNF-α, IL-6, oxidized low-density lipoprotein (oxLDL), and MPO levels were found to be significantly higher, while PON1 paraoxonase and arylesterase activities were nonsignificantly lower in the obese patients.
Strong significant negative correlations were found between plasma PAI-1 concentration and mean LDL size, as well as between PAI-1 concentrations and the levels of the large and intermediate high-density lipoprotein (HDL) subfractions.
In multiple regression analysis, PAI-1 was predicted by waist circumference and intermediate HDL subfraction.
Conclusion.
The significant correlations between PAI-1 levels and lipoprotein subfractions indicate the link between PAI-1 and lipid metabolism in obesity.
American Psychological Association (APA)
Somodi, Sándor& Seres, Ildikó& Lőrincz, Hajnalka& Harangi, Mariann& Fülöp, Péter& Paragh, György. 2018. Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects. International Journal of Endocrinology،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1172356
Modern Language Association (MLA)
Somodi, Sándor…[et al.]. Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects. International Journal of Endocrinology No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1172356
American Medical Association (AMA)
Somodi, Sándor& Seres, Ildikó& Lőrincz, Hajnalka& Harangi, Mariann& Fülöp, Péter& Paragh, György. Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects. International Journal of Endocrinology. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1172356
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1172356